Moreover, Dot1l expression could stratify ccRCC patients in pT stage, Fuhrman grade and SSIGN/ Leibovich subgroups, which might redefine individual risk stratification. This evidence concerns the gene DOT1L and nonpapillary renal cell carcinoma.